Few seroconversions were observed^1,2

Seroconversions from baseline to ≥96 weeks

• Of the seroconversions observed at ≥96 weeks, 1 participant in the DESCOVY arm and 4 participants in the FTC/TDF arm had suspected baseline infections
• At primary analysis, when 100% of participants reached Week 48 and ≥50% reached Week 96, 7 participants using DESCOVY seroconverted vs 15 participants using FTC/TDF

Adherence testing at primary analysis

• In a case-control substudy, dried blood spot testing measured intracellular TFV-DP levels in red blood cells and estimated number of daily doses at HIV diagnosis
• Median intracellular drug levels were substantially lower in participants infected with HIV-1 at the time of diagnosis vs uninfected, matched control participants. Values for 1 participant in the DESCOVY arm are not available

Seroconversions from baseline to ≥144 weeks³

• In addition to the seroconversions at ≥96 weeks, 3 additional seroconversions occurred in the DESCOVY arm (n=2070)